

# Katy Sanchez-Pozos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6336144/publications.pdf>

Version: 2024-02-01

10  
papers

198  
citations

1307366

7  
h-index

1474057

9  
g-index

10  
all docs

10  
docs citations

10  
times ranked

496  
citing authors

#	ARTICLE	IF	CITATIONS
1	Recovery from ischemic acute kidney injury by spironolactone administration. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3160-3169.	0.4	55
2	Diabetes susceptibility in Mayas: Evidence for the involvement of polymorphisms in HHEX, HNF4 $\beta$ , KCNJ11, PPAR $\gamma$ , CDKN2A/2B, SLC30A8, CDC123/CAMK1D, TCF7L2, ABCA1 and SLC16A11 genes. <i>Gene</i> , 2015, 565, 68-75.	1.0	52
3	Polymerized type I collagen reduces chronic cyclosporine nephrotoxicity. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2150-2158.	0.4	20
4	Shared genetic underpinnings of childhood obesity and adult cardiometabolic diseases. <i>Human Genomics</i> , 2019, 13, 17.	1.4	17
5	Síndrome metabólico en niños mexicanos: poca efectividad de las definiciones diagnósticas. <i>Endocrinología, Diabetes Y Nutrición</i> , 2017, 64, 369-376.	0.1	15
6	Genetic Component of Type 2 Diabetes in a Mexican Population. <i>Archives of Medical Research</i> , 2016, 47, 496-505.	1.5	14
7	Whole-exome sequencing in maya indigenous families: variant in PPP1R3A is associated with type 2 diabetes. <i>Molecular Genetics and Genomics</i> , 2018, 293, 1205-1216.	1.0	13
8	Pharmacogenetic Evaluation of Metformin and Sulphonylurea Response in Mexican Mestizos with Type 2 Diabetes. <i>Current Drug Metabolism</i> , 2020, 21, 291-300.	0.7	8
9	Genetic variability of <i>CYP2C9*2</i> and <i>CYP2C9*3</i> in seven indigenous groups from Mexico. <i>Pharmacogenomics</i> , 2016, 17, 1881-1889.	0.6	4
10	From Pharmacogenetics to Gene Expression: Implications for Precision Medicine in Diabetes. , 0, , .		0